NASDAQ:BLSM

BlossomHill Therapeutics Q3 2026 Earnings Results & Report

BlossomHill Therapeutics logo
$14.61 +0.02 (+0.14%)
As of 02:27 PM Eastern

BlossomHill Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$1.29 versus the -$0.93 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call
4:00 PM ET

BlossomHill Therapeutics EPS Results

Actual EPS
-$1.29
Consensus EPS
-$0.93
Beat/Miss
Missed by -$0.36
One Year Ago EPS
N/A

BlossomHill Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BlossomHill Therapeutics Q3 2026 Earnings FAQ

BlossomHill Therapeutics (NASDAQ:BLSM) reported earnings of -$1.29 per share for Q3 2026, missing the consensus estimate of -$0.93. The report was announced on Thursday, November 12, 2026.

BlossomHill Therapeutics Earnings Headlines

Your father's savings lost half their value after 1971.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
See More BlossomHill Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BlossomHill Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BlossomHill Therapeutics and other key companies, straight to your email.

About BlossomHill Therapeutics

BlossomHill Therapeutics (NASDAQ:BLSM) is a biotechnology company focused on developing medicines for cancer. Its research has centered on targeted small-molecule treatments designed to address cancer-related genetic changes.

The company’s pipeline has included BH-306, an investigational inhibitor of mutant IDH1 being developed for cancers associated with that mutation. The program is in development and is not a marketed treatment.

Publicly available information about the company’s leadership and geographic operations is limited.

View BlossomHill Therapeutics Profile